Case report
A 60-year-old otherwise healthy woman has been treated for epilepsy for 10 years. The first drug she was prescribed was carbamazepine, and 2 years ago vigabatrin was added at a dose of 500 mg q.i.d. A year later sodium valproate was also added. Six months after she started vigabatrin she developed photophobia, flickering lights and saw 'shadows at both sides'. On ocular examination her visual acuity was 20/20 both eyes. She could easily identify Ishihara plates. There was no afferent pupillary defect. Anterior segments and fundi were within normal limits. Intravenous fluorescein angiography did not reveal any abnormality. Automated field testing using the 30-2 program disclosed bilateral crescent-shaped nasal field defects (Fig. 1) . A 60-4 full threshold test showed marked annular peripheral field defects; 60-4 blue-on-yellow perimetry demonstrated denser annular scotomas (Fig. 2 ). Scotopic and photopic electroretinography (ERG) recordings were normal. On electro-oculography (EOG) the Arden ratios were clearly reduced (42% and 30% for the right and left eye respectively). Vigabatrin was tapered to 500 mg ti.d.
Photophobia and flashing lights have resolved. However, the visual field defects persisted without progression.
The patient is currently checked every 3 months.
Comment
Visual field defects reportedly develop in 30% of adult patients and in up to 65% of children taking vigabatrin?,3
These defects are usually symmetric, absolute and binasal, sparing the temporal field. Twenty-four hours later his temperature had lysed and he felt much better but the dark area in the upper lid had worsened and looked necrotic and crusted (Fig. 2) . 
